Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab After Ustekinumab Loss of Response in Chinese Crohn's Disease Patients
ChiCTR2500115639Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of guselkumab in Crohn's disease, sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Clinical remission at Week 48 (CDAI <150). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2500115639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115639.